Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v44-EN Version v2-FR
Language English French
Date Updated 2023-07-28 2022-03-14
Drug Identification Number 02243278 02243278
Brand name LORAZEPAM INJECTION USP LORAZEPAM INJECTION USP
Common or Proper name LORAZEPAM LORAZEPAM
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients LORAZEPAM LORAZEPAM
Strength(s) 4MG 4MG
Dosage form(s) SOLUTION LIQUID SOLUTION LIQUID
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 1ML 10LIVI 1ML 10LIVI
ATC code N05BA N05BA
ATC description ANXIOLYTICS ANXIOLYTICS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2022-09-19 2022-04-07
Actual start date 2022-09-19
Estimated end date 2022-12-23 Unknown
Actual end date 2022-12-21
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Inventory is available at Wholesalers on Allocation (100% of Historical demand). Allocation to remain in place until June 2023. Limited inventory has been allocated
Health Canada comments